TY - JOUR
T1 - Low-dose niacin supplementation improves motor function in us veterans with parkinson’s disease
T2 - A single-center, randomized, placebo-controlled trial
AU - Wakade, Chandramohan
AU - Chong, Raymond
AU - Seamon, Marissa
AU - Purohit, Sharad
AU - Giri, Banabihari
AU - Morgan, John C.
N1 - Funding Information:
Funding: The work was supported by Merit Review Award I01RX001613 issued by the Department of Veterans Affairs, Rehabilitation Research and Development to C.W., R.C., and J.C.M. The funder has no role in study design and conception, data acquisition and analysis, or interpretation of the data.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/12
Y1 - 2021/12
N2 - A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assigned to receive low-dose niacin or a placebo. At the end of the double-blind phase, all participants received open-label niacin for the next six months. All patients were evaluated at baseline, after six months, and after one year of treatment. The primary outcome measure was the Unified Parkinson’s Disease Rating Scale III (UPDRS III) scores. Secondary outcome measures were depression, sleep quality, mental flexibility and cognition, and physical fatigue. Niacin treatment was well-tolerated by forty-five subjects. The mean [95% CI] change in UPDRS III scores at six months of placebo was −0.05 [95% CI, −2.4 to 2.32], and niacin was −1.06 [95% CI, −3.68 to 1.57]. From six to twelve months when both groups received open-label niacin supplementation, the average UPDRS III scores significantly decreased for the placebo group by 4.58 [95% CI, −0.85 to 8.30] and the niacin group by 4.63 [95% CI, 1.42 to 7.83] points. Low-dose niacin supplementation is a well-tolerated adjunct therapy and may improve motor function in PD when taken over a longer period.
AB - A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assigned to receive low-dose niacin or a placebo. At the end of the double-blind phase, all participants received open-label niacin for the next six months. All patients were evaluated at baseline, after six months, and after one year of treatment. The primary outcome measure was the Unified Parkinson’s Disease Rating Scale III (UPDRS III) scores. Secondary outcome measures were depression, sleep quality, mental flexibility and cognition, and physical fatigue. Niacin treatment was well-tolerated by forty-five subjects. The mean [95% CI] change in UPDRS III scores at six months of placebo was −0.05 [95% CI, −2.4 to 2.32], and niacin was −1.06 [95% CI, −3.68 to 1.57]. From six to twelve months when both groups received open-label niacin supplementation, the average UPDRS III scores significantly decreased for the placebo group by 4.58 [95% CI, −0.85 to 8.30] and the niacin group by 4.63 [95% CI, 1.42 to 7.83] points. Low-dose niacin supplementation is a well-tolerated adjunct therapy and may improve motor function in PD when taken over a longer period.
KW - Fatigue
KW - Movement disorder
KW - Niacin
KW - Parkinson’s disease
KW - UPDRS III
UR - http://www.scopus.com/inward/record.url?scp=85121733277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121733277&partnerID=8YFLogxK
U2 - 10.3390/biomedicines9121881
DO - 10.3390/biomedicines9121881
M3 - Article
AN - SCOPUS:85121733277
SN - 2227-9059
VL - 9
JO - Biomedicines
JF - Biomedicines
IS - 12
M1 - 1881
ER -